OX40/OX40L antagonists (e.g., Oxelumab, Amlitelimab, Cudarolimab, Vonlerolizumab, Rocatinlimab) have demonstrated efficacy in atopic dermatitis, asthma, and ulcerative colitis, with notable therapeutic success in atopic dermatitis (141). This evidence concerns the gene TNFSF4 and atopic eczema.